Patents by Inventor Jesper Worm

Jesper Worm has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Oligonucleotide Agonists Targeting Progranulin
    Publication number: 20230287412
    Abstract: The present invention relates to oligonucleotides which up-regulate or restore the expression of progranulin in cells, and their use in the treatment of neurological disorders, and disorders associated with progranulin haploinsufficiency.
    Type: Application
    Filed: November 14, 2022
    Publication date: September 14, 2023
    Inventors: Ravi Jagasia, Lars Joenson, Soren Rasmussen, Disa Tehler, Dorthe Vang Larsen, Jesper Worm
  • OLIGONUCLEOTIDES COMPRISING A PHOSPHORODITHIOATE INTERNUCLEOSIDE LINKAGE
    Publication number: 20230002762
    Abstract: The present invention relates to an oligonucleotide comprising at least one phosphorodithioate internucleoside linkage of formula (I) (I) as defined in the description and in the claim. The oligonucleotide of the invention can be used as a medicement.
    Type: Application
    Filed: April 14, 2022
    Publication date: January 5, 2023
    Applicant: ROCHE INNOVATION CENTER COPENHAGEN A/S
    Inventors: Konrad Bleicher, Henrik Frydenlund HANSEN, Troels KOCH, Jesper WORM, Adrian SCHAEUBLIN, Erik FUNDER, Joerg DUSCHMALÉ, Lars JOENSON, Meiling LI, Martina Brigitte DUSCHMALÉ, Yong WU, Xi SHU
  • Oligonucleotide Progranulin Agonists
    Publication number: 20220403388
    Abstract: The present invention relates to oligonucleotides that upregulate or restore the expression of progranulin in cells by targeting the promoter region of the progranulin gene. The invention further relates to pharmaceutical compositions and methods for the treatment of diseases associated with progranulin, specifically progranulin haploinsufficiency and neurological disorders.
    Type: Application
    Filed: June 6, 2022
    Publication date: December 22, 2022
    Inventors: Lars Joenson, Soren V. Rasmussen, Jesper Worm, Dorthe Vang Larsen, Johannes Braun
  • Antisense Oligonucleotide for Targeting Progranulin
    Publication number: 20220204973
    Abstract: The present invention relates to oligonucleotides which alter the splicing pattern of progranulin in cells, and their use in the treatment of neurological disorders.
    Type: Application
    Filed: December 16, 2021
    Publication date: June 30, 2022
    Inventors: Ravi Jagasia, Lars Jonson, Soren Rasmussen, Jacob Ravn, Disa Tehler, Dorthe Vang, Jesper Worm
  • OLIGONUCLEOTIDE AGONISTS TARGETING PROGRANULIN
    Publication number: 20210388357
    Abstract: The present invention relates to oligonucleotides which up-regulate or restore the expression of progranulin in cells, and their use in the treatment of neurological disorders, and disorders associated with progranulin haploinsufficiency.
    Type: Application
    Filed: May 13, 2021
    Publication date: December 16, 2021
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Ravi JAGASIA, Lars JOENSON, Søren RASMUSSEN, Disa TEHLER, Dorthe Vang LARSEN, Jesper WORM
  • MICRORNA-134 BIOMARKER
    Publication number: 20210270845
    Abstract: The invention relates to the field of secondary markers for microRNA activity, and in particular the invention relates to the identification of Serpine1 as a mRNA which is repressed by microRNA-134 in neuronal cells, and the use of Serpine1 mRNA or protein as a biomarker for microRNA-134 modulation, such as a biomarker for antisense oligonucleotide inhibitors of microRNA-134.
    Type: Application
    Filed: February 23, 2021
    Publication date: September 2, 2021
    Applicant: Roche Innovation Center Copenhagen A/S
    Inventors: Jesper Worm, Lukasz Kielpinski
  • OLIGONUCLEOTIDES COMPRISING A PHOSPHORODITHIOATE INTERNUCLEOSIDE LINKAGE
    Publication number: 20200339982
    Abstract: The present invention relates to an oligonucleotide comprising at least one phosphorodithioate internucleoside linkage of formula (I) (I) as defined in the description and in the claim. The oligonucleotide of the invention can be used as a medicament.
    Type: Application
    Filed: December 21, 2018
    Publication date: October 29, 2020
    Applicant: Roche Innovation Center Copenhagen A/S
    Inventors: Konrad BLEICHER, Henrik Frydenlund HANSEN, Troels KOCH, Jesper WORM, Adrian SCHAEUBLIN, Erik FUNDER, Joerg DUSCHMALÉ, Lars JOENSON, Meiling LI, Martina Brigitte DUSCHMALÉ, Yong WU, Xi SHU
  • METHODS FOR TREATING ANDROGEN RECEPTOR DEPENDENT DISORDERS INCLUDING CANCERS
    Publication number: 20140031409
    Abstract: The invention provides the combination use of antisense oligomers targeting androgen receptor mRNA and androgen receptor binding inhibitors that reduce androgen receptor activity for the treatment of androgen receptor related medical disorders, such as cancers, particularly prostate cancers and breast cancers.
    Type: Application
    Filed: April 30, 2013
    Publication date: January 30, 2014
    Applicants: Santaris Pharma A/S, Enzon Pharmaceuticals
    Inventors: Jesper Worm, Yixian Zhang
  • Micro-RNA mediated modulation of colony stimulating factors
    Patent number: 8492357
    Abstract: The present invention relates to the modulation of immunoregulatory proteins, including cytokines, such as colony stimulatory factors (CSF) via the use of microRNA-155 modulators.
    Type: Grant
    Filed: July 24, 2009
    Date of Patent: July 23, 2013
    Assignee: Santaris Pharma A/S
    Inventors: Jesper Worm, Jan Stenvang, Susanna Obad, Sakari Kauppinen
  • Methods for treating androgen receptor dependent disorders including cancers
    Patent number: 8450290
    Abstract: The invention provides the combination use of antisense oligomers targeting androgen receptor mRNA and androgen receptor binding inhibitors that reduce androgen receptor activity for the treatment of androgen receptor related medical disorders, such as cancers, particularly prostate cancers and breast cancers.
    Type: Grant
    Filed: November 12, 2010
    Date of Patent: May 28, 2013
    Assignees: Enzon Pharmaceuticals, Inc., Santaris Pharma A/S
    Inventors: Jesper Worm, Yixian Zhang
  • RNA antagonists targeting Hsp27
    Patent number: 8440809
    Abstract: The present invention relates to oligomer compounds (oligomers), which target Hsp27 mRNA in a cell, leading to reduced expression of Hsp27. Reduction of Hsp27 expression is beneficial for the treatment of certain medical disorders, such as cancer. The invention provides therapeutic compositions comprising oligomers and methods for modulating the expression of Hsp27 using the oligomers, including methods of treatment.
    Type: Grant
    Filed: July 1, 2009
    Date of Patent: May 14, 2013
    Assignee: Santaris Pharma A/S
    Inventor: Jesper Worm
  • Micro-RNA Mediated Modulation of Colony Stimulating Factors
    Publication number: 20120115924
    Abstract: The present invention relates to the modulation of immunoregulatory proteins, including cytokines, such as colony stimulatory factors (CSF) via the use of microRNA-155 modulators.
    Type: Application
    Filed: July 24, 2009
    Publication date: May 10, 2012
    Applicant: Santaris Pharma A/S
    Inventors: Jesper Worm, Jan Stenvang, Susanna Obad, Sakari Kauppinen
  • COMPOUNDS FOR THE MODULATION OF BETA-CATENIN EXPRESSION
    Publication number: 20120004288
    Abstract: The invention relates to oligomer compounds (oligomers), which target beta-catening mRNA in a cell, leading to reduced expression of beta-catenin. Reduction of beta-catenin expression is beneficial for a range of medical disorders, such as hyperproliferative disorders, such as cancer. The invention provides therapeutic compositions comprising oligomers and methods for modulating the expression of beta-catenin using said oligomers, including methods of treatment.
    Type: Application
    Filed: September 14, 2011
    Publication date: January 5, 2012
    Applicants: SANTARIS PHARMA A/S, ENZON PHARMACEUTICALS, INC.
    Inventor: Jesper WORM
  • LNA ANTAGONISTS TARGETING THE ANDROGEN RECEPTOR
    Publication number: 20110319471
    Abstract: The invention relates to oligonucleotide compounds (oligomers), which target androgen receptor mRNA in a cell, leading to reduced expression of the androgen receptor. Reduction of the androgen receptor expression is beneficial for the treatment of certain disorders, such as a hyperproliferative disorders (e.g., cancer). The invention provides therapeutic compositions comprising oligomers and methods for modulating the expression of androgen receptor using said oligomers, including methods of treatment.
    Type: Application
    Filed: May 31, 2011
    Publication date: December 29, 2011
    Applicants: SANTARIS PHARMA A/S, ENZON PHARMACEUTICALS, INC.
    Inventor: Jesper WORM
  • Compounds for the modulation of beta-catenin expression
    Patent number: 8039446
    Abstract: The invention relates to oligomer compounds (oligomers), which target beta-catenin mRNA in a cell, leading to reduced expression of beta-catenin. Reduction of beta-catenin expression is beneficial for a range of medical disorders, such as hyperproliferative disorders, such as cancer. The invention provides therapeutic compositions comprising oligomers and methods for modulating the expression of beta-catenin using said oligomers, including methods of treatment.
    Type: Grant
    Filed: September 2, 2010
    Date of Patent: October 18, 2011
    Assignees: Enzon Pharmaceuticals, Inc., Santaris Pharma A/S
    Inventor: Jesper Worm
  • LNA antagonists targeting the androgen receptor
    Patent number: 7989429
    Abstract: The invention relates to oligonucleotide compounds (oligomers), which target androgen receptor mRNA in a cell, leading to reduced expression of the androgen receptor. Reduction of the androgen receptor expression is beneficial for the treatment of certain disorders, such as a hyperproliferative disorders (e.g., cancer). The invention provides therapeutic compositions comprising oligomers and methods for modulating the expression of androgen receptor using said oligomers, including methods of treatment.
    Type: Grant
    Filed: March 18, 2010
    Date of Patent: August 2, 2011
    Assignees: Enzon Pharmaceuticals, Inc., Santaris Pharma A/S
    Inventor: Jesper Worm
  • METHODS FOR TREATING ANDROGEN RECEPTOR DEPENDENT DISORDERS INCLUDING CANCERS
    Publication number: 20110152348
    Abstract: The invention provides the combination use of antisense oligomers targeting androgen receptor mRNA and androgen receptor binding inhibitors that reduce androgen receptor activity for the treatment of androgen receptor related medical disorders, such as cancers, particularly prostate cancers and breast cancers.
    Type: Application
    Filed: November 12, 2010
    Publication date: June 23, 2011
    Applicant: Enzon Pharmaceuticals, Inc.
    Inventors: Jesper Worm, Yixian Zhang
  • RNA ANTAGONISTS TARGETING HSP27
    Publication number: 20110144185
    Abstract: The present invention relates to oligomer compounds (oligomers), which target Hsp27 mRNA in a cell, leading to reduced expression of Hsp27. Reduction of Hsp27 expression is beneficial for the treatment of certain medical disorders, such as cancer.
    Type: Application
    Filed: July 1, 2009
    Publication date: June 16, 2011
    Applicants: ENZON PHARMACEUTICALS, INC., SANTARIS PHARMA A/S
    Inventor: Jesper Worm
  • COMPOUNDS FOR THE MODULATION OF BETA-CATENIN EXPRESSION
    Publication number: 20110086902
    Abstract: The invention relates to oligomer compounds (oligomers), which target beta-catenin mRNA in a cell, leading to reduced expression of beta-catenin. Reduction of beta-catenin expression is beneficial for a range of medical disorders, such as hyperproliferative disorders, such as cancer. The invention provides therapeutic compositions comprising oligomers and methods for modulating the expression of beta-catenin using said oligomers, including methods of treatment.
    Type: Application
    Filed: September 2, 2010
    Publication date: April 14, 2011
    Applicants: SANTARIS PHARMA A/S, ENZON PHARMACEUTICALS, INC.
    Inventor: Jesper WORM
  • Compounds for the modulation of beta-catenin expression
    Patent number: 7915401
    Abstract: The invention relates to oligomer compounds (oligomers), which target beta-catenin mRNA in a cell, leading to reduced expression of beta-catenin. Reduction of beta-catenin expression is beneficial for a range of medical disorders, such as hyperproliferative disorders, such as cancer. The invention provides therapeutic compositions comprising oligomers and methods for modulating the expression of beta-catenin using said oligomers, including methods of treatment.
    Type: Grant
    Filed: January 21, 2009
    Date of Patent: March 29, 2011
    Assignees: Enzon Pharmaceuticals, Inc., Santaris Pharma A/S
    Inventor: Jesper Worm